Indivumed and University of Rochester Unite for Cancer Therapeutics

Indivumed and the University of Rochester Medical Center (URMC) have announced a significant expansion of their partnership aimed at advancing precision oncology. This collaboration, confirmed on December 10, 2025, focuses on developing novel therapeutics for patients facing high medical needs in cancer care.

Leveraging Expertise for Patient-Centric Research

The partnership combines Indivumed’s expertise in standardized tissue and clinical data collection with URMC’s renowned research capabilities at the Wilmot Cancer Institute. Together, they aim to enhance patient-centric cancer research and drug development, addressing the urgent need for innovative cancer therapies.

Indivumed’s platform utilizes meticulously obtained surgical tissue samples and extensive clinical data to drive research initiatives. URMC’s role in this collaboration includes the collection and processing of high-quality biosamples, adhering to Indivumed’s strict standard operating procedures, which reduce ischemia time to under ten minutes. This expedited process ensures the integrity and quality of the samples used in research.

The joint research efforts will prioritize the creation of patient-derived tumor models (PDTMs) from the collected samples. These models will include classical cell cultures, spheroids, and organoids, providing critical insights for the identification, validation, and development of new cancer molecular targets.

Focus on Advanced Cancer Types

The partnership initially targets advanced stages of solid tumors, such as colorectal cancer (CRC), pancreatic cancer (PDAC), lung cancer, and breast cancer. There is potential for the collaboration to expand to other cancer types in the future. Insights gained will not only advance Indivumed’s ongoing research initiatives but will also assist clinicians in making informed therapeutic decisions.

Hartmut Juhl, CEO and founder of Indivumed, expressed enthusiasm about the collaboration, stating, “We are thrilled to deepen our collaboration with URMC, significantly enhancing our ability to identify novel cancer therapeutics in a truly patient-centered approach.” He emphasized the commitment to developing primary tumor models for testing new compounds, leveraging Indivumed’s unique AI-powered data analysis capabilities.

With this agreement, URMC joins the Indivumed Global Clinical Network, which includes several prominent hospitals and leading oncology institutes across North America, Europe, and Asia. This network aims to facilitate the sharing of knowledge and resources, building on successful previous collaborations, including a recent publication regarding new classification methods for distinct types of colon cancer.

About the Partners

The Wilmot Cancer Institute, part of the University of Rochester, is an NCI-Designated Cancer Center serving over three million people across 27 counties in New York. It offers specialty cancer care and research services through a network of 13 locations, supported by over 190 oncology physicians and approximately 115 scientists dedicated to cancer research.

Indivumed is a biotech company specializing in precision oncology, focused on discovering novel therapeutic targets for cancer treatments. With more than twenty years of experience, Indivumed aims to redefine oncology and ensure that every cancer patient benefits from precise and effective therapies.

This collaboration represents a significant step forward in the fight against cancer, combining the strengths of two leading institutions to accelerate the discovery and development of innovative treatments.